The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study
Open accessAbstract
BACKGROUND: In Germany, most breast cancer patients are treated in specialized breast cancer units (BCU), which are certified, and routinely monitored. Herein, we evaluate up-to-date oncological outcome of breast cancer (BC) molecular subtypes in routine clinical care of a specialized BCU. METHODS: The study was a prospectively single-center cohort study of 4102 female cases with primary, unilateral, non-metastatic breast cancer treated between 01 January 2003 and 31 December 2012. The five routinely used molecular subtypes (Luminal A-like, Luminal B/HER2 negative-like, Luminal B/HER2 positive-like, HER2-type, Triple negative) were analyzed. The median follow-up time of the whole cohort was 55 months. We calculated estimates for local control rate (LCR), disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and relative overall survival (ROS). RESULTS: Luminal A-like tumors were the most frequent (44.7 %) and showed the best outcome with LCR of 99.1 % (95 % CI 98.5; 99.7), OS of 95.1 % (95 % CI 93.7; 96.5), and ROS of 100.0 % (95 % CI 98.5; 101.5). Triple negative tumors (12.3 %) presented the poorest outcome with LCR of 89.6 % (95 % CI 85.8; 93.4), OS of 78.5 % (95 % CI 73.8; 83.3), and ROS of 80.1 % (95 % CI 73.8; 83.2). CONCLUSIONS: Patients with a favorable subtype can expect an OS above 95 % and an LCR of almost 100 % over 5 years. On the other hand the outcome of patients with HER2 and Triple negative subtypes remains poor, thus necessitating more intensified research and care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Cited by
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Molecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 450
Pathology of triple negative breast cancer
Borri, F., & Granaglia, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.005 · Cited by 300
Hernström, V., Josefsson, V., Sartor, H., Schmidt, D., Larsson, A.-M., Hofvind, S., Andersson, I., Rosso, A., Hagberg, O., & Lång, K. (2025) · The Lancet Digital Health · doi:10.1016/s2589-7500(24)00267-x · Cited by 174
Ringwald, J., Gerstner, L., Junne, F., Ziser, K., Schäffeler, N., Wallwiener, M., Hautzinger, M., Bäuerle, A., Brucker, S., Zipfel, S., et al. (2019) · PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie · doi:10.1055/a-0835-6905 · Cited by 12
Metadata
- Authors
- Hennigs, A., Riedel, F., Gondos, A., Sinn, P., Schirmacher, P., Marmé, F., Jäger, D., Kauczor, H.-U., Stieber, A., Lindel, K., Debus, J., Golatta, M., Schütz, F., Sohn, C., Heil, J., & Schneeweiss, A.
- Venue
- BMC Cancer
- Published
- 2016-09-15
- Volume
- 16
- Issue
- 1
- Pages
- 734-734
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2519246239
- Cited by
- 199
- References
- 1
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. https://app.cochat.ai/papers/10.1186/s12885-016-2766-3
- The paper
- Hennigs, A., Riedel, F., Gondos, A., Sinn, P., Schirmacher, P., Marmé, F., Jäger, D., Kauczor, H.-U., Stieber, A., Lindel, K., Debus, J., Golatta, M., Schütz, F., Sohn, C., Heil, J., & Schneeweiss, A. (2016). Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-016-2766-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.